|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Joinstar Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Joinstar Biomedical Technology Co., Ltd.
01 Mar 2020·Journal of global antimicrobial resistanceQ3 · MEDICINE
Genome analysis of a multidrug-resistant Streptococcus sanguis isolated from a throat swab of a child with scarlet fever
Q3 · MEDICINE
Article
Author: Yuanyuan Wen ; Li Xie ; Qingjun Jia ; Le Wang ; Qinglin Cheng ; Yinyan Huang ; Wei Liu ; Tingting Huang
OBJECTIVES:A multidrug-resistant strain of the opportunistic pathogen Streptococcus sanguis (S28) was isolated from a throat swab of a child with scarlet fever as a rare case. Genome sequencing and analysis of strain S28 were performed to gain a better understanding of the multidrug resistance mechanisms of S. sanguis and its relationship with scarlet fever.
METHODS:The genome of S. sanguis S28 was sequenced on a Illumina HiSeq platform. Genome assembly was conducted using SOAPdenovo v.2.04 and the assembled genome sequence was submitted to NCBI for annotation.
RESULTS:The 1 268 358 696bp genome of S. sanguis S28 contains 2287 coding sequences (CDS) with a GC content of 43.2%. Strain S28 possesses four antimicrobial resistance genes (ARGs), which is consistent with phenotypic analysis. A novel transposon with three genes conferring resistance to macrolide-lincosamide-streptogramin B (MLSB) antibiotics, tetracyclines and aminoglycosides was discovered.
CONCLUSION:To our knowledge, this is the first report of a S. sanguis genome isolated from a throat swab of a child with scarlet fever and the first report of a transposon with three activated ARGs conferring resistance to MLSB, tetracyclines and aminoglycosides together.
100 Deals associated with Joinstar Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Joinstar Biomedical Technology Co., Ltd.